CTLA4 and nonpapillary renal cell carcinoma: Therefore, we found that the response to anti‐PD‐1 and anti‐CTLA4 treatments was closely correlated with the expression levels of EMX2OS and TLN2 in ccRCC patients (Figure 7D,J).